Symbiosis Pharmaceutical Services Achieves Zero GMP Observations in FDA Gene Therapy Inspection
Key Insights
Symbiosis Pharmaceutical Services (search) successfully completed a seven-day FDA inspection of its Scotland facilities with zero GMP observations, focusing on AAV (search) viral vector biologics manufacturing.
The inspection validates the company's quality management systems and capabilities in sterile manufacturing for gene therapy products, particularly strengthening its position in biologics fill/finish services.
Symbiosis is expanding its operations with a new automated sterile GMP manufacturing facility in Stirling, UK, to meet growing demand for injectable drug product manufacturing services.
Symbiosis Pharmaceutical Services (search) has achieved a significant regulatory milestone following a comprehensive FDA inspection of its Scottish facilities, receiving zero GMP observations. The seven-day inspection, conducted in January 2025, focused specifically on the company's fill/finish operations for AAV (search) (Adeno-Associated Virus (search)) viral vector biologics manufactured for a major US pharmaceutical client.
The successful inspection outcome reinforces Symbiosis' position as a trusted partner in global biologics sterile manufacturing, particularly in the growing field of gene therapy production. The regulatory review thoroughly examined the company's quality management systems and manufacturing processes for complex biological products.
Quality Excellence and Regulatory Compliance
Colin MacKay, CEO of Symbiosis, emphasized the importance of this achievement: "Achieving this successful FDA inspection outcome is a reflection of our team's expertise and on-going commitment to quality excellence. In a rapidly evolving biopharmaceutical landscape, regulatory rigour and GMP operational performance are enduring priorities for the company and a fundamental part of our business and cultural ethos."
The company has maintained its regulatory excellence through continuous enhancement of its quality functions, including the ongoing recruitment of experienced quality professionals and strengthening of process controls and risk management frameworks. This proactive approach has enabled Symbiosis to maintain a constant state of regulatory readiness.
Expansion and Growth Strategy
In response to increasing market demand, Symbiosis is commissioning a new state-of-the-art automated sterile GMP manufacturing facility near its existing operations in Stirling, UK. This expansion will significantly enhance the company's commercial-scale sterile manufacturing capabilities, enabling support for a broader range of clients throughout their injectable drug product lifecycle.
"Symbiosis continues to thrive as a specialist fill/finish global CMO leader, fuelled by a sustained increase in demand for its services which align with broader industry trends such as the number of biologics and injectable drugs in development and an increasing appetite for outsourced sterile GMP fill/finish services," MacKay noted.
The company's growth strategy focuses on maintaining high standards in both customer service and quality compliance, particularly targeting the US and European markets. This latest regulatory success positions Symbiosis strongly in the competitive contract manufacturing landscape, especially for advanced therapy medicinal products.